1 | Actemra, MRA | [1] Tocilizumab Tocilizumab | [1] D02596
D02596
| [1] IL6R IL6R 💬 | [12] Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 107 107 |
2 | MRA | - | - | - | - | [2] 46 46, 107 |
3 | MRA (Actemra) | [1] Tocilizumab Tocilizumab | [1] D02596
D02596
| [1] IL6R IL6R 💬 | [12] Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 107 107 |
4 | MRA (Tocilizumab) | [1] Tocilizumab Tocilizumab | [1] D02596
D02596
| [1] IL6R IL6R 💬 | [12] Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2] 46 46, 107 |
5 | MRA 003 US | - | - | - | - | [1] 49 49 |
6 | MRA(Tocilizumab) | [1] Tocilizumab Tocilizumab | [1] D02596
D02596
| [1] IL6R IL6R 💬 | [12] Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2] 46 46, 107 |
7 | MRA, Actemra | [1] Tocilizumab Tocilizumab | [1] D02596
D02596
| [1] IL6R IL6R 💬 | [12] Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2] 46 46, 107 |
8 | MRA-SC | - | - | - | - | [1] 46 46 |
9 | Tocilizumab (MRA-SC) | [1] Tocilizumab Tocilizumab | [1] D02596
D02596
| [1] IL6R IL6R 💬 | [12] Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 40 40 |